However, the small increase in SMN due to the curcumin treatment could be attributed to the low efficiency of the SMN2 human promoter with respect to the SMN1 promoter [16] that is present in the SMA mouse. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.